Medical News

RSS

New study may pave way for novel therapeutic strategies for COVID-19

An international and multidisciplinary team led by researchers at the University of Oxford, University of Glasgow, and University of Heidelberg, has uncovered the interactions that SARS-CoV-2 RNA establishes with the host cell, many of which are fundamental for infection.

25 May 2021

Newly identified small molecule can be used to rejuvenate the brain, counteract memory loss

Alzheimer's disease is the main cause of dementia and current therapeutic strategies cannot prevent, slow down or cure the pathology.

25 May 2021

A new model to prevent or manage caffeine withdrawal after surgery

Millions of people consume caffeine in coffee, tea, sodas and energy drinks, but when they go without, the withdrawal symptoms can include drowsiness, difficulty concentrating and intense headaches.

25 May 2021

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

A research group from Osaka University led by Professor Hisashi Arase and consisting of researchers from the Research Institute for Microbial Diseases, the Institute for Protein Research, the Immunology Frontier Research Center, the Center for Infectious Diseases, and the Graduate School of Medicine has discovered for the first time that both neutralizing antibodies that protect against infection as well as infection-enhancing antibodies that increase infectivity are produced after infection with SARS-CoV-2 by analyzing antibodies derived from COVID-19 patients.

25 May 2021

New technology makes it easier to diagnose neurodegenerative diseases

A new combination of optical coherence tomography (OCT), adaptive optics and deep neural networks should enable better diagnosis and monitoring for neuron-damaging eye and brain diseases like glaucoma.

25 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

Study sheds new light on the memory function of sleep in humans

While we sleep, the brain produces particular activation patterns. When two of these patterns - slow oscillations and sleep spindles - gear into each other, previous experiences are reactivated.

25 May 2021

New technique using "soft" X-rays offers a simpler way to gain insight into nanocarriers

Before the huge potential of tiny nanocarriers for highly targeted drug delivery and environmental clean-up can be realized, scientists first need to be able to see them.

25 May 2021

New testing protocol for SARS-CoV-2 can process thousands of samples within 48 hours

Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.

25 May 2021

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Researchers at the Leiden University Medical Center demonstrated that low-micromolar concentrations of 6′,6′-difluoro24 aristeromycin (DFA), an adenosine nucleoside analog, strongly inhibits the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) in a cell-based infection assay.

25 May 2021

Corporations encourage employee vaccination but stop short of mandates

Many of the companies with the largest number of employees say they'll do almost anything to encourage their employees to get vaccinated.

25 May 2021

Pandemic leads doctors to rethink unnecessary treatment

Covid-19 is opening the door for researchers to address a problem that has vexed the medical community for decades: the overtreatment and unnecessary treatment of patients.

25 May 2021

Colorado lawmakers wage multifront assault on high drug costs

Tired of waiting for federal action to reduce prescription drug costs, Colorado is acting on its own — even if it must do so with one arm tied behind its back.

25 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Researchers examine effect of depression on mother-infant relationship

In a study funded by National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC) researchers examined whether depression, either before or during pregnancy, affects the mother-infant relationship. The research was published today (Tuesday 25 May) in BJPsych Open.

25 May 2021

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

A team of scientists from Germany has recently evaluated the reactogenicity profile of heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination among healthcare workers. The findings reveal that a 12-week interval regimen of heterologous vaccination is well-tolerated among participants. The study is currently available on the medRxiv* preprint server.

25 May 2021

Researchers explore strategies that could help the homeless during pandemics

A team of UBC Okanagan researchers is looking at strategies that could help the homeless during a pandemic.

25 May 2021

UIC leads multi-center collaborative to help communities affected by COVID-19

The University of Illinois Chicago has been selected by the National Institutes of Health as the principal site of a multi-center collaborative in the Chicago area that will bolster research and outreach to help communities disproportionately affected by COVID-19.

25 May 2021